|
gptkbp:instanceOf
|
gptkb:drug
peptide
|
|
gptkbp:administeredBy
|
subcutaneous injection
oral tablet
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:A10BJ06
|
|
gptkbp:brand
|
gptkb:Ozempic
gptkb:Rybelsus
gptkb:Wegovy
|
|
gptkbp:CASNumber
|
gptkb:910463-68-2
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:developedBy
|
gptkb:Novo_Nordisk
|
|
gptkbp:effect
|
promotes weight loss
reduces blood glucose
suppresses appetite
|
|
gptkbp:eliminationHalfLife
|
about 7 days
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:halfLife
|
about 1 week
|
|
gptkbp:hasMolecularFormula
|
C187H291N45O59
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
semaglutide
|
|
gptkbp:KEGGID
|
D10568
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:MedlinePlusID
|
a617007
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:patent
|
gptkb:Novo_Nordisk
|
|
gptkbp:pregnancyCategory
|
C (US)
not recommended in pregnancy
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
gptkb:DB13928
52083456
56843331
|
|
gptkbp:riskFactor
|
pancreatitis
gallbladder disease
hypoglycemia (with insulin or sulfonylureas)
|
|
gptkbp:routeOfAdministration
|
oral
subcutaneous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
constipation
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:UNII
|
R7J9XJ08N3
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
obesity
|
|
gptkbp:bfsParent
|
gptkb:GLP-1_receptor_agonists
|
|
gptkbp:bfsLayer
|
6
|